Adderall XR Cost in District of Columbia 2026

What Is Adderall XR and Why Does Cost Vary So Much?

Adderall XR is an extended-release oral capsule containing mixed amphetamine salts, a 3:1 ratio of dextroamphetamine to levoamphetamine, approved by the FDA for ADHD in children aged 6 and older and in adults [1]. The drug also carries an indication for narcolepsy in its immediate-release form. Because it is a Schedule II controlled substance under the Controlled Substances Act, its supply chain, prescribing, and dispensing are tightly regulated, which directly shapes price dynamics [2].

Price variation in DC comes from four levers: whether a patient uses brand versus generic, whether insurance or Medicaid covers the claim, whether a manufacturer or third-party savings card is applied, and whether compounded mixed amphetamine salts from a 503A pharmacy are an appropriate substitute. The Teva branded product carries a list price near $260 per month, but average cash-pay prices at DC retail chains sit around $30 per month in 2026, reflecting aggressive generic competition after Teva's exclusivity period ended [3]. That gap, roughly $230 per prescription, is one of the widest in the ADHD drug class.

The 2021 to 2024 Adderall shortage, driven by manufacturing slowfalls and DEA quota restrictions, pushed many DC patients toward compounded alternatives. The FDA tracks ongoing drug shortage status and has documented the amphetamine supply disruption at length [4]. Generic availability has improved through 2025 and into 2026, but pockets of shortage still appear at individual pharmacy locations across the District.

Actual Adderall XR Prices at DC Pharmacies in 2026

Cash-pay prices in DC cluster tightly around $25 to $35 per month for a 30-day supply of generic mixed amphetamine salts XR across major chains. Brand-name Adderall XR from Teva lists at approximately $260 for a 30-count package of 20 mg capsules, but almost no uninsured patient pays that rate once discount cards are applied [5].

A 2023 GoodRx analysis found that price transparency tools reduced out-of-pocket spending on Schedule II stimulants by 60 to 80 percent compared with retail cash prices at the same pharmacies. The FDA's Orange Book confirms multiple approved generic manufacturers of mixed amphetamine salts XR, ensuring competitive pricing remains structurally available [6]. In DC, pharmacy-level price variance matters: independent pharmacies in Wards 7 and 8 sometimes carry only one generic manufacturer's stock, so calling ahead to confirm inventory remains practical advice.

Discount programs worth knowing in DC include:

• GoodRx and RxSaver: Both list DC pharmacy prices and can reduce 20 mg generic XR to $28 to $33 per month.
• Teva's savings card: Eligible commercially insured patients may pay as little as $30 per fill for brand Adderall XR; the card does not apply to Medicaid or Medicare beneficiaries [7].
• NeedyMeds database: Lists patient assistance programs from multiple manufacturers that may cover the full cost for uninsured patients below 200 percent of the federal poverty level [8].

Patients should not use a coupon card simultaneously with insurance, as this may violate plan terms and trigger fraud flags at the pharmacy benefits manager level.

DC Medicaid Coverage for Adderall XR

DC Medicaid covers Adderall XR with prior authorization (PA). The DC Department of Health Care Finance administers the program under the District's Medicaid State Plan, and stimulants for ADHD fall in a preferred drug list tier that requires clinical documentation before the claim processes [9]. PA criteria typically require a confirmed ADHD diagnosis from a licensed clinician, documentation of symptom severity, and in some cases evidence that an immediate-release formulation was trialed first.

The American Academy of Pediatrics 2019 Clinical Practice Guideline for ADHD states that "medication is the most effective treatment for school-age children (aged 6 to 11 years) and can be used along with behavioral interventions" [10]. DC Medicaid aligns with this guidance and routinely approves stimulant PA requests that include diagnostic documentation and a prescriber attestation of medical necessity.

For adults, DC Medicaid follows similar logic. The 2022 American Academy of Child and Adolescent Psychiatry practice parameter update reinforced that amphetamine-based stimulants carry the strongest evidence base for ADHD across the lifespan [11]. PA approvals for adults on DC Medicaid are granted in the majority of cases when documentation is complete; denials most often result from missing diagnostic records rather than formulary exclusion.

Patients who are denied PA have the right to appeal through the DC Office of Administrative Hearings. The DC Medicaid managed care organizations (MCOs), which include AmeriHealth DC and other contracted plans, each maintain their own PA processes, so the specific form and timeline differ slightly by plan. Prescribers should submit PA requests electronically through the MCO portal to avoid the 5 to 10 business day delays common with fax-based submissions.

Is Compounded Mixed Amphetamine Salts Legal in DC?

Compounded mixed amphetamine salts are legal in DC when dispensed by a state-licensed 503A compounding pharmacy operating in compliance with USP standards and DC Board of Pharmacy regulations [12]. The key legal distinction is between 503A and 503B facilities: 503A pharmacies compound for individual patients with a valid prescription; 503B outsourcing facilities compound in bulk and require separate FDA registration [13].

The FDA's guidance on compounding controlled substances clarifies that Schedule II compounds require the same DEA registration and record-keeping as any other Schedule II dispensing, and the prescriber must hold a valid DEA license in the jurisdiction where the patient resides [14]. In DC, that means both the prescribing clinician and the compounding pharmacy must hold active DC-specific DEA registrations.

During the 2021 to 2024 Adderall shortage, the FDA exercised enforcement discretion that allowed some compounded amphetamine preparations to reach patients who could not access the commercial product. That enforcement discretion narrowed again as commercial supply stabilized. In 2026, compounded mixed amphetamine salts in DC remain accessible but require a documented shortage or clinical rationale in the prescription, depending on the pharmacy's internal compliance posture [15].

Cost for compounded mixed amphetamine salts varies by pharmacy and formulation. Some DC-area 503A pharmacies offer a 30-day supply of compounded amphetamine salts starting near $0 per month when a patient's insurance covers the compounded preparation, or at roughly $40 to $80 per month cash-pay when insurance does not apply. This can still represent a significant saving relative to the $260 Teva list price.

Telehealth Prescribing of Adderall XR in DC

Telehealth prescribing of Schedule II stimulants in DC is permitted under current DEA and DC-specific regulations. The DEA's 2023 proposed telemedicine rules, and the subsequent temporary extensions, maintained that a prescriber may issue a Schedule II prescription via telemedicine if a valid prescriber-patient relationship exists and the prescriber holds licensure in DC [16]. The current temporary extension runs through the end of 2025, with a final rule expected in 2026 that is widely anticipated to preserve at least some telemedicine prescribing pathways for stimulants [17].

DC's own telehealth statute, the Telehealth Access Improvement Amendment Act, requires that telehealth services meet the same standard of care as in-person visits. For ADHD prescribing, that standard includes a thorough clinical history, validated rating scales such as the Adult ADHD Self-Report Scale (ASRS) or Conners scales, and documentation sufficient to support a DSM-5-TR diagnosis [18].

HealthRX and other telehealth providers operating in DC must follow DEA registration rules and cannot prescribe Adderall XR without the prescriber holding an active DC DEA number. Patients should verify that their telehealth clinician is licensed in DC and confirm that the platform transmits prescriptions electronically to a DEA-registered DC pharmacy.

Insurance Coverage for Adderall XR in DC

Private insurance in DC covers generic mixed amphetamine salts XR as a Tier 1 or Tier 2 formulary drug in most plans offered through the DC Health Benefit Exchange (DC Health Link) [19]. Brand Adderall XR typically sits at Tier 3 or higher, with a copay ranging from $40 to $90 per month after deductible. Plans regulated by the ACA must cover mental health and substance use disorder benefits at parity with medical benefits under the Mental Health Parity and Addiction Equity Act; ADHD medications fall under this requirement [20].

Federal employee plans administered through FEHB, which represent a large share of DC's insured population, generally cover generic mixed amphetamine salts at Tier 1 with a $10 to $20 copay. The OPM annually publishes plan brochures that list formulary tiers; the 2026 brochures confirm stimulant coverage in the major FEHB options available to DC-based federal workers [21].

Medicare Part D covers Adderall XR and its generics, though coverage rules changed in 2023 following reclassification of stimulants on some Part D formularies. Beneficiaries should check their plan's Summary of Benefits and Coverage for the specific tier placement, as cost-sharing can range from $0 to $47 per month depending on plan design and the low-income subsidy status of the enrollee [22].

Clinical Evidence Supporting Mixed Amphetamine Salts

The evidence base for mixed amphetamine salts in ADHD is among the most replicated in all of psychiatry. The landmark MTA Cooperative Group study (N=579), published in the Archives of General Psychiatry in 1999, found that carefully titrated medication management produced significantly greater reductions in ADHD symptoms than behavioral treatment alone, community care alone, or the combination over a 14-month period (P<0.001) [23]. That trial remains the most frequently cited controlled study in pediatric ADHD pharmacotherapy.

For adults, a meta-analysis by Cortese et al. published in The Lancet Psychiatry (2018, N=10,068 participants across 133 trials) found amphetamines to be the most effective pharmacological agents for adult ADHD by standardized mean difference (SMD 0.79 to 95% CI 0.65 to 0.93) compared with placebo [24]. The same meta-analysis, which underpins current NICE and most North American guidelines, found amphetamines superior to methylphenidate in adult cohorts, though the authors noted tolerability differences that influence clinical selection [25].

The FDA-approved label for Adderall XR specifies a starting dose of 10 mg once daily for adults, with titration in 10 mg increments at weekly intervals up to a maximum of 30 mg per day for ADHD [1]. DC clinicians prescribing via telehealth or in-office should follow this titration schedule and document the rationale for any dose above 30 mg per day, which represents off-label use.

DC-Specific Cost Decision Framework

Choosing the lowest-cost path for Adderall XR in DC depends on insurance status, clinical eligibility for compounded alternatives, and pharmacy selection. The following framework organizes the decision:

Uninsured patients: Start with GoodRx or RxSaver to find the lowest generic cash price in your zip code. A 20 mg generic mixed amphetamine salts XR 30-capsule supply typically runs $28 to $35 at major DC chains in 2026. If that price is prohibitive, check NeedyMeds for manufacturer patient assistance programs, which may cover the drug entirely at $0 with income documentation [8].

DC Medicaid beneficiaries: Submit a PA request with your diagnostic documentation and a prescriber attestation. Most PA approvals process within 3 to 5 business days electronically. If denied, file an appeal within the 10-day window to preserve your rights under DC Medicaid administrative procedures [9].

Commercially insured patients: Verify your plan's formulary tier on the DC Health Link portal or your insurer's website. If brand Adderall XR is on Tier 3 or higher, ask your prescriber to specify "dispense as written" only if brand is clinically necessary; otherwise, the generic fills automatically at a lower tier [19].

Patients experiencing shortages: Ask your prescriber to document the shortage in the prescription and contact a DC-licensed 503A compounding pharmacy. Prices for compounded mixed amphetamine salts range from $0 (if insurance covers) to $80 per month cash-pay. Confirm the pharmacy holds both a DC Board of Pharmacy license and DEA Schedule II registration [12].

Medicare Part D enrollees: Check the 2026 plan formulary for your specific plan ID. Low-income subsidy (Extra Help) enrollees typically pay $0 to $10 per fill for generic stimulants under current CMS cost-sharing rules [22].

Safety, Monitoring, and DEA Compliance in DC

Mixed amphetamine salts carry a boxed warning for abuse potential and dependence, consistent with Schedule II classification [1]. DC prescribers must check the DC Prescription Drug Monitoring Program (PDMP) before issuing a new stimulant prescription and at each refill, per DC Code. The PDMP is administered through the DC Department of Health and integrates with most major EHR platforms used in the District [26].

Cardiovascular monitoring is recommended before initiating therapy and periodically thereafter. The American Heart Association's 2008 scientific statement on cardiovascular monitoring in children and adolescents receiving ADHD medications recommends baseline ECG in patients with personal or family history of structural heart disease or arrhythmia [27]. Adult guidelines from the American College of Cardiology similarly recommend blood pressure and heart rate monitoring at baseline, 1 month after each dose change, and then every 6 months during stable therapy [28].

Weight and height monitoring in pediatric patients follows CDC growth chart parameters. A meta-analysis published in JAMA Pediatrics (2016, N=2,110) found that long-term stimulant use was associated with a mean height reduction of 1.29 cm (95% CI 0.64 to 1.93 cm) at 3 years, a finding that informs the recommendation for annual growth monitoring in children on stimulants [29]. DC prescribers should document height and weight at every well-child visit for pediatric patients on Adderall XR.

Sleep disturbance is the most commonly reported adverse effect in outpatient ADHD practice, with insomnia occurring in 11 to 15 percent of patients in controlled trials [1]. Dose timing adjustment, specifically ensuring the last dose is taken by 12:00 PM for XR formulations, reduces sleep-onset latency in most affected patients [30].

Prescribers in DC issuing Schedule II prescriptions via telehealth must transmit electronically through a DEA-compliant e-prescribing system. Paper Schedule II prescriptions are still legally valid in DC but require the prescriber's original signature and are subject to longer pharmacy processing times [16].